Last deal

$250K

Amount

Seed

Stage

28.04.2022

Date

1

all rounds

$250K

Total amount

General

About Company
VVector Bio provides viral vector manufacturing services for cell and gene therapy, vaccine development, and novel medicines.

Industry

Sector :

Subsector :

founded date

01.01.2019

Number of employees

Company Type

For Profit

Last funding type

Seed

IPO status

Private

Description

VVector Bio specializes in manufacturing Lentivirus vectors, adeno-associated virus (AAV), recombinant adenovirus vectors, enveloped virus-like particles (eVLPs), and recombinant proteins. They offer process and analytical development for viral vector manufacturing, with a focus on Lentivirus vectors and AAV from HEK-293 suspension cells. Additionally, they provide manufacturing services for AAV from the baculovirus-insect cell system. The company's goal is to make cell and gene therapy accessible to every patient by innovating and creating a more efficient and cost-effective manufacturing process. They offer biomanufacturing services to accelerate the development and commercialization of novel medicines.
Contacts

Social url